A prospective randomized international multicenter study to compare Short versus Long Adjuvant immunotherapy after radical surgery of stage IIb-c, III and IV cutaneous malignant Melanoma (Grand SLAM)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509994-22-00

Enrollment

1800

Registered

2024-10-10

Start date

2024-11-15

Completion date

Unknown

Last updated

2025-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous malignant melanoma

Brief summary

Distant metastatic free survival (DMFS) and relapse free survival (RFS).

Detailed description

Overall survival (OS)

Interventions

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Distant metastatic free survival (DMFS) and relapse free survival (RFS).	—

Secondary

Measure	Time frame
Overall survival (OS)	—

Countries

Finland, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026